Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus

Journal of Infectious Diseases

Volumn 178, Issue 6, 1998, Pages 1734-1742

  Roilides, Emmanuel ^b   Anastasiou Katsiardani, Anastasia ^b   Dimitriadou Georgiadou, Anastasia ^b   Kadiltsoglou, Isaac ^b   Tsaparidou, Sevasti ^b   Panteliadis, Christos ^b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ARTICLE; CANDIDA ALBICANS; HOSPITAL INFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MONOCYTE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

CANDIDA ALBICANS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-10; KINETICS; MONOCYTES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; PHAGOCYTOSIS; STAPHYLOCOCCUS AUREUS; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE;

EID: 0031767503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314479     Document Type: Article

References (11)

1. Beck-Sague CM, Jarvis WR, National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
2. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
3. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
4. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995;155:1177-84.
5. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992;15:508-24.
6. Dale DC. Potential role of colony-stimulating factors in the prevention and treatment of infectious diseases. Clin Infect Dis 1994;18(suppl 2):S180-8.
7. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997;16:51-5.
8. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993;11:165-90.
9. Levitz SM, Tabuni A, Nong SH, Golenbock DT. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect Immun 1996;64:945-51.
10. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol 1992;148:3578-82.
11. Sieling PA, Abrams JS, Yamamura M, et al. Immunosuppressive roles for IL-10 and IL-4 in human infection. J Immunol 1993;150:5501-10.